Transapical Transcatheter Mitral Valve Replacement Trial Raises Questions
PHOENIX — Global experience with the novel Intrepid transapical transcatheter mitral valve replacement (TMVR) device through 2 years showed high risks of mortality and complications, raising concerns that might not be alleviated by the planned shift to a transfemoral approach. In the analysis pooling data from a pilot study and the APOLLO trial, the high-risk […]